The H3 antagonist, ciproxifan, alleviates the memory impairment but enhances the motor effects of MK-801 (dizocilpine) in rats.

Neuropharmacology
Mark E BardgettMolly S Griffith

Abstract

Antagonists of H(3)-type histamine receptors exhibit cognitive-enhancing properties in various memory paradigms as well as evidence of antipsychotic activity in normal animals. The present study determined if a prototypical H(3) antagonist, ciproxifan, could reverse the behavioral effects of MK-801, a drug used in animals to mimic the hypoglutamatergic state suspected to exist in schizophrenia. Four behaviors were chosen for study, locomotor activity, ataxia, prepulse inhibition (PPI), and delayed spatial alternation, since their modification by dizocilpine (MK-801) has been well characterized. Adult male Long-Evans rats were tested after receiving a subcutaneous injection of ciproxifan or vehicle followed 20 min later by a subcutaneous injection of MK-801 or vehicle. Three doses of MK-801 (0.05, 0.1, & 0.3 mg/kg) increased locomotor activity. Each dose of ciproxifan (1.0 & 3.0 mg/kg) enhanced the effect of the moderate dose of MK-801, but suppressed the effect of the high dose. Ciproxifan (3.0 mg/kg) enhanced the effects of MK-801 (0.1 & 0.3 mg/kg) on fine movements and ataxia. Deficits in PPI were observed after treatment with MK-801 (0.05 & 0.1 mg/kg), but ciproxifan did not alter these effects. Delayed spatial alternation w...Continue Reading

References

Dec 1, 1992·Archives of General Psychiatry·S Park, P S Holzman
Jan 1, 1990·Psychopharmacology·D F WozniakJ P Miller
Jan 1, 1996·Journal of Neural Transmission·M HasegawaT Nabeshima
Mar 1, 1997·Behavioural Brain Research·M E BardgettJ G Csernansky
Aug 1, 2000·Brain Research. Developmental Brain Research·P S JacobsM E Bardgett
Dec 1, 2001·Neurobiology of Learning and Memory·S D Berry, M A Seager
Jun 14, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Barbara K LipskaBita Moghaddam
Feb 28, 2003·The Journal of Pharmacology and Experimental Therapeutics·Gerard B FoxArthur A Hancock
Feb 28, 2003·The Journal of Pharmacology and Experimental Therapeutics·Timothy A EsbenshadeArthur A Hancock
Jun 26, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Daniel S LorrainLinda J Bristow
Jan 31, 2004·Pharmacology, Biochemistry, and Behavior·Neal R SwerdlowPamela P Auerbach
May 26, 2004·Proceedings of the National Academy of Sciences of the United States of America·Mark E JacksonBita Moghaddam
Feb 3, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Elena H ChartoffRichard D Palmiter
Apr 29, 2005·The International Journal of Neuropsychopharmacology·Monica M MarcusTorgny H Svensson
Oct 11, 2005·Neurobiology of Learning and Memory·Mark E BardgettShannon M O'Connell
Aug 23, 2006·Journal of Neurochemistry·Raphaël FaucardJean-Michel Arrang
Nov 30, 2006·Biochemical Pharmacology·P BonaventureT Lovenberg
Sep 21, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Mark E BardgettMolly S Griffith
Oct 26, 2007·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Houman Homayoun, Bita Moghaddam
Feb 29, 2008·The Journal of Pharmacology and Experimental Therapeutics·Siyuan LeHervé Schaffhauser
Jan 28, 2009·Behavioral Neuroscience·Deborah J WatsonMark E Stanton

❮ Previous
Next ❯

Citations

Jul 24, 2012·Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.]·Dong Dong ZhangKlaus Scholich
Aug 19, 2015·Neuropharmacology·Maximiliano Rapanelli, Christopher Pittenger
May 1, 2012·Pharmacology, Biochemistry, and Behavior·Guy GriebelEtienne Guillot
Sep 18, 2015·Journal of Experimental Neuroscience·D MahmoodM Akhtar
May 17, 2019·CNS Neuroscience & Therapeutics·Frédéric ChauveauDaniel Beracochea
Apr 19, 2016·Journal of Basic and Clinical Physiology and Pharmacology·Danish MahmoodDipanjan Goswami
Dec 20, 2014·Medical Science Monitor : International Medical Journal of Experimental and Clinical Research·Andrzej BrodziakAlicja Różyk-Myrta
Jan 1, 2014·Cerebellum & Ataxias·Bin LiJian-Jun Wang
Aug 3, 2021·Frontiers in Neuroscience·Elliott Carthy, Tommas Ellender

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-N-Methyl-D-Aspartate Receptor Encephalitis

Anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis is a form of of brain inflammation due to antibodies against NMDA receptors. Discover the latest research on anti-NMDA receptor encephalitis here.

Ataxias (MDS)

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.

Addiction

This feed focuses mechanisms underlying addiction and addictive behaviour including heroin and opium dependence, alcohol intoxication, gambling, and tobacco addiction.

Basal Forebrain- Circuits

Basal forebrain is a region in the brain important for production of acetylcholine and is the major cholinergic output of the CNS. Discover the latest research on circuits in the basal forebrain here.

Ataxia

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Ataxias

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on different types of ataxias here.